Investigational New Drugs

, Volume 12, Issue 2, pp 103–110 | Cite as

Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)

  • Perry Guaglianone
  • Kenneth Chan
  • Eduardo DelaFlor-Weiss
  • Rosemarie Hanisch
  • Susan Jeffers
  • Desh Sharma
  • Franco Muggia
Phase I Studies


We have completed a phase I and pharmacology study of liposomally-encapsulated daunorubicin (DaunoXome). Of 32 patients entered, 30 were evaluable. No toxicity was encountered at the initial doseescalation steps from 10 to 60 mg/m2. At 80 mg/m2, two patients manifested grade 2 neutropenia. At least grade 3 neutropenia occurred in all patients receiving 120 mg/m2. Alopecia and subjective intolerance were mild. Cardiotoxicity was not observed except for an episode of arrhythmia in a patient with lung cancer and prior radiation. Only one minor objective response was observed in this population of refractory solid tumors. Pharmacokinetics differed from those of the free drug with no detection of daunorubicinol. We recommend future phase II studies with a dose of 100 mg/m2 in previously treated and 120 mg/m2 of DaunoXome in previously untreated patients with solid tumors.

Key words

daunorubicin liposomes pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rinehart JJ, Lewis RP, Balcerzack SP: Adriamycin cardiotoxicity in man. Ann Intern Med 81:475–478, 1974Google Scholar
  2. 2.
    Von Hoff D, Rozencweig M, Piccart M: Cardiotoxicity of anticancer agents. Semin Oncol 9:23–27, 1982Google Scholar
  3. 3.
    Me Vie JG: Anthracycline analogs and carriers. In: Muggia FM (ed): Cancer treatment and the heart, p. 92. Johns Hopkins University Press, 1992Google Scholar
  4. 4.
    Endicott JA, Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137–171, 1989Google Scholar
  5. 5.
    Rahman YE, Hanson WR, Bharucha J, Ainsworth EJ, Jaroslow BN: Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation. Ann NY Acad Sci 308:325–341, 1987Google Scholar
  6. 6.
    Juliano R, Stamp D: Pharmacokinetics of liposome-encapsulated antitumor drugs. Biochem Pharm 27:21–27, 1978Google Scholar
  7. 7.
    Gabizon A: Liposomes as a drug delivery system in cancer chemotherapy. In: Drug Carrier Systems, p. 185. John Wiley & Sons Ltd., 1989Google Scholar
  8. 8.
    Forssen EA, Coulter DM, Profitt RT: Selectivein vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52:3255–3261, 1992Google Scholar
  9. 9.
    Gabizon A, Meshorer A, Barenholz Y: Comparative long-term study of the toxicities of free and liposomeassociated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 77:459–469, 1986Google Scholar
  10. 10.
    Gabizon A, Shiota R, Papahadjopoulos D: Pharma-cokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 81:1484–1488, 1989Google Scholar
  11. 11.
    Papahadjopoulos D, Allen TJ, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee K-D, Woodle MC, Lasic DD, Redemann C, Martin FJ: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460–11464, 1991Google Scholar
  12. 12.
    Khatibi S, Howell SB, McCully C, Balis F, Poplack DG, Kim S: Prolongation of drug action in CSF by encapsulation into multivesicular liposomes (abstr.). Proc Am Soc Clin Oncol 10:282, 1991Google Scholar
  13. 13.
    Gabizon A, Goren D, Fuks Z, Meshorer A, Barenholz Y: Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Br J Cancer 51:681–689, 1985Google Scholar
  14. 14.
    Mayhew EG, Goldrosen MH, Vaage J, Rustum YM: Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. J Natl Cancer Inst 78:707–713, 1987Google Scholar
  15. 15.
    Fichtner I, Reszka R, Elbe B, Arndt D: Therapeutic evaluation of liposome-encapsulated daunoblastin in murine tumor models. Neoplasma 28:141–149, 1981Google Scholar
  16. 16.
    Perez-Soler R, Priebe W: Anthracycline antibiotics with high liposome entrapment: structural features and biological activity. Cancer Res 50:4260–4266, 1990Google Scholar
  17. 17.
    Fichtner I, Arndt D, Elbe B, Reszka R: Cardiotoxicity of free and liposomally encapsulated daunorubicin in mice. Oncology 41:363–369, 1984Google Scholar
  18. 18.
    Rahman A, Fumagalli A, Goodman A, Schein PS: Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity. Semin Oncol 11(4) (suppl.) 3:45–48, 1984Google Scholar
  19. 19.
    Storm G, Roerdinck FH, Steerenberg PA, de Jongh WH, Crommelin DJA: Influence of lipid composition on the antitumor activity exerted by doxorubicin containing liposomes in a rat solid tumor model. Cancer Res 47:3366–3372, 1987Google Scholar
  20. 20.
    Hwang KJ, Padki MM, Chow DD, Essien HE, Lai JY, Beaumier PL: Uptake of small liposomes by non-reticuloendothelial tissues. Biochem Biophys Acta 901:88–96, 1987Google Scholar
  21. 21.
    Gabizon A, Price DC, Huberty J, Bresalier RS, Papahadjopoulos D: Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res 50:6371–6378, 1990Google Scholar
  22. 22.
    Warren BA: The vascular morphology of tumors. In: Peterson HI (ed), Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow in Experimental and Human Tumors, pp. 1–47. Boca Raton, FL: CRC Press Inc., 1979Google Scholar
  23. 23.
    Proffitt RT, Williams LE, Presant CA, Tin GW, Uliana JA, Gamble RC, Baldeschwieler JD: Tumor imaging potential of liposomes loaded with In-111-NT A: biodistribution in mice. J Nucl Med 24:45–51, 1983Google Scholar
  24. 24.
    Presant CA, Proffitt RT, Turner AF, Williams LE, Winsor D, Werner JL, Kennedy P, Wisemand C, Gala K, McKenna RJ, Smith JD, Bouzaglou SA, Callahan RA, Baldeschwieler J, Crossley RJ: Successful imaging of human cancer with Indium-111-labeled phospholipid vesicles. Cancer 62:905–911, 1988Google Scholar
  25. 25.
    Treat J, Greenspan A, Forst D, Sanchez JA, Ferrans VJ, Potkul LA, Woolley PV, Rahman A: Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst 82:1706–1710, 1990Google Scholar
  26. 26.
    Gabizon A, Peretz T, Sulkes A, Ben-Yosef R, Ben-Baruch N, Catane R, Biran S, Barenholz Y: Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol 25:1795–1803, 1989Google Scholar
  27. 27.
    Rahman A, Treat J, Roh J, Potkul LA, Alvord WG, Forst D, Woolley PV: A phase I clinical trial and pharmacokinetic evaluation of liposome encapsulated doxorubicin. J Clin Oncol 8:1093–1100, 1990Google Scholar
  28. 28.
    Lohri A, Gelmon KA, Embree L, Mayer L, Cullis P, Saletan S, Goldie J: Phase I/II of liposomes encapsulated doxorubicin (TLC-D99) in non-small celllung cancer (NSCLC) (abstr.). Proc Am Soc Clin Oncol 10:106, 1991Google Scholar
  29. 29.
    Oudard S, Thierry A, Jorgensen TJ, Rahman A: Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 28:259–265, 1991Google Scholar
  30. 30.
    Thierry A, Vige D, Coughlin SS, Belli JA, Dritschilo, Rahman A: Modulation of doxorubicin resistance in multidrug-resistant cells by liposome. FASEB 7:572–579, 1993Google Scholar
  31. 31.
    Mickisch GH, Rahman A, Pastan I, Gottesman MM: Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. J Natl Cancer Inst 84:804–805, 1992Google Scholar
  32. 32.
    Sharma D, Muggia F, Lucci L, Chan K, Forssen E, Gill P: Liposomal daunorubicin (VS103): tolerance and clinical effects in AIDS-related Kaposi's Sarcoma during a phase I study (abstr.). Proc Am Soc Clin Oncol 9:9, 1990Google Scholar
  33. 33.
    Oken M, Creech R, Tormey D: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin One 5:649–655, 1982Google Scholar
  34. 34.
    Chan KK, Watson E: GLC-mass spectrometry of several important anticancer drugs II: doxorubicin and daunorubicin aglycone analogs. J Pharm Sci 67:1748–1752, 1978Google Scholar
  35. 35.
    Watson E, Chan KK: Rapid analytic methods for adriamycin and metabolites in human plasma by thin film fluorescence scanner. Cancer Treat Rep 60:1611–1615, 1972Google Scholar
  36. 36.
    Huffman DH, Benjamin RS, Bachur NR: Daunorubicin metabolism in acute lymphocytic leukemia patients. Clin Pharmacol Ther 13:895–905, 1972Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Perry Guaglianone
    • 1
  • Kenneth Chan
    • 1
    • 2
  • Eduardo DelaFlor-Weiss
    • 1
  • Rosemarie Hanisch
    • 1
  • Susan Jeffers
    • 1
  • Desh Sharma
    • 1
  • Franco Muggia
    • 1
  1. 1.Division of Medical OncologyUniversity of Southern CaliforniaLos Angeles
  2. 2.Comprehensive Cancer CenterThe Ohio State UniversityColumbusUSA

Personalised recommendations